Follow-up pre-seed equity round

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES
eliminating the need for prophylactiC antibiotics
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis

HOME
News
Follow-up pre-seed equity round

Follow-up pre-seed equity round

27 MISK secured to validate in-vivo results

January 1, 2022

Akthelia has secured a closed follow-up bridge funding round. 12 existing shareholders, bought shares for a total of 27 mISK.

The plan for the investment is to conduct further animal studies, define target product profile and position the company to be institutional investor ready.

Febrile neutropenia is a common, life-threatening complication of chemotherapy

Gut barrier Injury and Neutrophil depletion puts patients at risk for bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT BACTERAEMIA BY STRENGTHENING INNATE GUT BARRIER DEFENSES

eliminating the need for prophylactiC antibiotics

reducing risk of serious adverse events, antimicrobial resistance and microbiome dysbiosis

Follow-up pre-seed equity round

27 MISK secured to validate in-vivo results

Febrile neutropenia is a common,
life-threatening
complication of chemotherapy

Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis

AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES

reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis